Clinical, Neurological, Neurophysiological, and Immunogenetic Mechanisms of Trigeminal Neuralgia Development and Treatment Optimization

Abstract

Background: Trigeminal neuralgia (TN) is a severe neuropathic facial pain disorder traditionally attributed to neurovascular compression. However, contemporary evidence demonstrates a multifactorial pathogenesis involving focal demyelination, sodium channel dysregulation, central sensitization, and immunogenetic susceptibility.

Objective: To integrate clinical, neuroanatomical, neurophysiological, and immunogenetic mechanisms underlying TN and propose a precision-based treatment optimization model.

Methods: A structured narrative synthesis was conducted using PubMed, Scopus, and Web of Science (2015–2024). Studies focusing on imaging biomarkers, electrophysiology, cytokine profiling, sodium channel genetics, and surgical outcomes were analyzed.

Results: TN development involves: (1) focal demyelination at the trigeminal root entry zone, (2) ephaptic cross-excitation, (3) Nav1.7/Nav1.8 upregulation, (4) microglial activation and cytokine elevation (TNF-α, IL-6), and (5) thalamocortical sensitization. Microvascular decompression shows 5-year pain freedom rates of ~70–80%, whereas pharmacologic tolerance limits long-term medical therapy efficacy.

Conclusion: TN is a neurovascular–neuroimmune disorder. Multimodal stratification integrating imaging, electrophysiology, and immunogenetics can significantly enhance individualized treatment strategies in neurology practice.